AVDL
Avadel PharmaceuticalsAVDL
AVDL
About: Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.
Employees: 188
0
Funds holding %
of 7,457 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
79% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 24
27% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 45
8% more funds holding
Funds holding: 157 [Q4 2024] → 170 (+13) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 7 [Q4 2024] → 7 (+0) [Q1 2025]
2.05% less ownership
Funds ownership: 82.24% [Q4 2024] → 80.19% (-2.05%) [Q1 2025]
27% less capital invested
Capital invested by funds: $833M [Q4 2024] → $610M (-$223M) [Q1 2025]
44% less call options, than puts
Call options by funds: $2.25M | Put options by funds: $3.99M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$19
111%
upside
Avg. target
$20
122%
upside
High target
$21
133%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Needham Ami Fadia 28% 1-year accuracy 44 / 157 met price target | 111%upside $19 | Buy Reiterated | 8 May 2025 |
HC Wainwright & Co. Oren Livnat 51% 1-year accuracy 22 / 43 met price target | 133%upside $21 | Buy Reiterated | 4 Mar 2025 |
Financial journalist opinion
Based on 11 articles about AVDL published over the past 30 days
Positive
Zacks Investment Research
2 days ago
All You Need to Know About Avadel (AVDL) Rating Upgrade to Buy
Avadel (AVDL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Positive
Seeking Alpha
2 days ago
Avadel Pharmaceuticals: Moving Nicely Through An 'Inflection Year'
Avadel Pharmaceuticals is gaining momentum with strong Q1 results, a key legal win, and moving swiftly to profitability. LUMRYZ, Avadel's once-daily sodium oxybate, is growing rapidly and could enter the idiopathic hypersomnia market after a favorable court ruling. Analysts remain bullish, reiterating Buy ratings and projecting significant revenue and profit growth through FY2026 as LUMRYZ adoption accelerates.
Neutral
GlobeNewsWire
4 days ago
Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer
DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- DUBLIN, May 13, 2025 – Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the appointment of Susan Rodriguez as Chief Operating Officer. In this newly created role, Ms. Rodriguez will lead all aspects of the Company's commercial strategy, structure, organization, and related operations, including supply chain.
Neutral
GlobeNewsWire
4 days ago
Avadel Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20 at 12:00 p.m.
Positive
Zacks Investment Research
5 days ago
Earnings Estimates Moving Higher for Avadel (AVDL): Time to Buy?
Avadel (AVDL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Positive
Zacks Investment Research
5 days ago
Wall Street Analysts Believe Avadel (AVDL) Could Rally 100.21%: Here's is How to Trade
The mean of analysts' price targets for Avadel (AVDL) points to a 100.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
GlobeNewsWire
1 week ago
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to nine (9) new employees to purchase 51,700 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as an inducement material to the employee's acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee's respective start date and 25% vesting on the second, third, and fourth anniversary thereafter. The options are subject to the terms and conditions of Avadel's 2021 Inducement Plan approved by the Board of Directors in November 2021 and the terms and conditions of award agreements covering the grants.
Neutral
Seeking Alpha
1 week ago
Avadel Pharmaceuticals plc (AVDL) Q1 2025 Earnings Call Transcript
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q1 2025 Earnings Conference Call May 7, 2025 9:00 AM ET Company Participants Austin Murtagh - IR Greg Divis - CEO Tom McHugh - CFO Conference Call Participants Andrew Tsai - Jefferies David Amsellem - Piper Sandler Mark Goodman - Leerink David Huang - Deutsche Bank Myriam Belghiti - LSC Ami Fadia - Needham Chase Knickerbocker - Craig Hallum Operator Greetings, and welcome to Avadel Pharmaceuticals First Quarter 2025 Earnings Call. At this time, all participants are in a listen only mode.
Neutral
GlobeNewsWire
1 week ago
Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance
-- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year over year increase over the first quarter of 2024 --
Neutral
GlobeNewsWire
1 week ago
Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction
- With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia - - Federal Circuit decision permits new clinical trials and further development of LUMRYZ™ for the treatment of indications beyond narcolepsy - DUBLIN, Ireland, May 06, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced that the United States Court of Appeals for the Federal Circuit (the “Federal Circuit”) has ruled in favor of Avadel, overturning important parts of the injunction imposed by the U.S. District Court for the District of Delaware (the “Delaware Court”) regarding LUMRYZ™ as a potential treatment of indications beyond narcolepsy. The Federal Circuit vacated the portion of the injunction that prohibited Avadel from applying for FDA approval of LUMRYZ for any indication beyond narcolepsy, calling the district court's analysis “simply too speculative and tenuous.
Charts implemented using Lightweight Charts™